Quantiphi, an award-winning AI-first digital engineering company announced it has acquired a strategic minority interest in leading stem cell-based biotech innovator Transcell, marking a milestone in AI-supported drug discovery in the life sciences industry.
Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the strategic investment aligns with Quantiphi’s decade-plus commitment to solve what matters for enterprises.
“This partnership will help pharma ascertain the safety profile of their novel molecules on human stem cell composed microphysiologies, reduce the need for animal testing and accelerate preclinical decisions and batch release processes for biotherapeutics and vaccines,” Marhok said. “Use of ethical and responsible AI will help with automated bioassay implementation and support scientists in accelerated decision-making processes.”
Also Read: Persist AI & Nivagen Partner on AI for Injectable Manufacturing
Transcell Biologics Founder and CEO Dr. Subhadra Dravida said Quantiphi’s investment and involvement are crucial for advancing Transcell’s mission to support animal-free testing strategies as enterprise solutions.
“This collaboration aims to bring adult stem cell technology into practical applications and ultimately improve treatment outcomes,” Dravida said. “Through these synergistic efforts, we are propelling innovation and elevating industry standards for efficient cost and time management.”
Quantiphi Corporate Development Head Dipen Shah said Quantiphi and Transcell are seamlessly integrating AI and biotech to drive advancements in drug discovery and development processes.
“Quantiphi will continue to consider other strategic partnerships and investments across the value chain – from early-stage research to clinical trials – as aligned with our growth and innovation strategy to enhance customer value,” Shah said.
Source: PRNewswire
